STOCK TITAN

FOXO Technologies Inc. - FOXO STOCK NEWS

Welcome to our dedicated page for FOXO Technologies news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO Technologies stock.

FOXO Technologies Inc. (symbol: FOXO) is leading the charge in transforming the global longevity and life insurance industries through cutting-edge epigenetic technology and AI-driven solutions. Founded under the names Yousurance and Life Epigenetics, the company has redefined how we understand and measure health and aging.

FOXO’s core business revolves around commercializing longevity science by utilizing epigenetic biomarkers to assess the biological age and health status of individuals. This revolutionary approach not only impacts life insurance underwriting protocols but also engages consumers directly through an advanced platform.

With a focus on DNA methylation, FOXO leverages supervised machine learning and artificial intelligence to pinpoint molecular signs of aging and health conditions. This enables more accurate risk assessment and personalized health insights, setting new standards in the insurance sector.

Recent achievements include groundbreaking advancements in epigenetic research and the integration of AI to enhance the precision of health evaluations. The company's current projects aim to further refine these technologies and expand their application range, ensuring they remain at the forefront of innovation in their field.

Financially, FOXO Technologies Inc. is committed to sustained growth and solidifying its market presence through strategic partnerships and continual investment in research and development. Their collaborations with leading scientific institutions and industry partners underscore their commitment to excellence and innovation.

Stay updated with the latest news and developments to see how FOXO Technologies Inc. continues to shape the future of longevity and health insurance.

Rhea-AI Summary

FOXO Technologies Inc. (NYSE American: FOXO) has received a notice of non-compliance from NYSE Regulation due to reporting stockholders' deficit of ($14.9) million as of March 31, 2024, and losses from continuing operations and/or net losses in its three most recent fiscal years ended December 31, 2023. The company is now subject to procedures outlined in Section 1009 of the Company Guide and remains under conditions from previous notifications for stockholders' equity noncompliance and past due listing fee noncompliance.

Interim CEO Mark White attributed the delinquency to short-term capital allocation strategies and expressed the company's intention to present a compliance plan, highlighting recent planned acquisitions expected to generate meaningful cashflow. FOXO aims to regain compliance with NYSE American continued listing standards in the near future, though there are no guarantees. If compliance is not achieved by the respective deadlines, NYSE may initiate delisting proceedings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
Rhea-AI Summary

FOXO Technologies has regained compliance with SEC reporting requirements after filing its Form 10-Q for the quarter ending March 31, 2024. Interim CEO Mark White expressed confidence in timely future filings and addressing NYSE American deficiencies. FOXO is closing a transaction with Rennova Health to acquire rural hospital operations in Tennessee and has completed the Myrtle Recovery Centers transaction, securing $2.5M in additional capital. Myrtle Recovery Centers, operational since August 2023, is expected to generate $3-4M annually. The Scott County hospital acquisition awaits shareholder approval and is expected to close in Q3 2024. Combined, Myrtle Recovery Centers and Scott County Community Hospital generated unaudited net revenue of $18.7M and net income of $5.2M for the year ending December 31, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.39%
Tags
none
-
Rhea-AI Summary

FOXO Technologies has secured up to $2.8 million in Senior Notes from an institutional investor to fund the acquisition of Myrtle Recovery Centers and provide additional working capital. The acquisition, along with the planned purchase of Scott County Community Hospital, is expected to be transformative for the company, which reported combined unaudited net revenue of approximately $18.7 million and net income of $5.2 million for 2023. Interim CEO Mark White expressed optimism about the strategic fit of these acquisitions with FOXO's epigenetic and AI-based solutions. Further details are available in the Company's Form 8-K filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
Rhea-AI Summary

FOXO Technologies has received a non-compliance notice from the NYSE American due to overdue listing fees exceeding 180 days. The company missed the June 7, 2024 deadline for payment but has since settled the fees. FOXO's Interim CEO, Mark White, attributed the delay to short-term capital allocation strategies, including planned acquisitions expected to boost cash flow. Despite the delinquency, FOXO aims to regain compliance with NYSE standards soon. The company is now under the procedures outlined in Section 1009 of the NYSE Company Guide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.07%
Tags
none
-
Rhea-AI Summary

On June 14, 2024, FOXO Technologies announced two share exchange agreements with Rennova Health to acquire healthcare operations. The deals involve Myrtle Recovery Centers and Scott County Community Hospital (doing business as Big South Fork Medical Center). Myrtle Recovery Centers will be exchanged for $500,000 in FOXO common stock, while Scott County Community Hospital will be exchanged for $20 million in convertible preferred stock. These acquisitions are expected to generate significant cash flow for FOXO, with the acquired entities reporting $18.7 million in net revenue and $5.2 million in net income for 2023. The integration aims to leverage FOXO’s epigenetic technology in community health and addiction recovery, potentially expanding market reach and improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.92%
Tags
-
Rhea-AI Summary
FOXO Technologies Inc. received a Notice of Non-Compliance from NYSE for failing to file its Annual Report on Form 10-K by the due date. Despite challenges, the company is committed to regaining compliance, improving financial systems, and advancing transformative transactions to drive shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
none
Rhea-AI Summary
FOXO Technologies Inc. announces a proposed merger with M2i Global, Inc. to focus on securing the nation's supply of critical materials and resources. The merger aims to develop a global value supply chain for critical minerals for the U.S. government and free trade partners, as well as create a strategic mineral reserve in partnership with the U.S. Federal Government. The collaboration brings together extensive experience, knowledge, and resources to drive value for shareholders and enhance operational efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
-
Rhea-AI Summary
FOXO Technologies Inc. appoints Francis Colt deWolf to its Board of Directors, bringing over 20 years of experience in the financial services sector. The Company also received a notice of noncompliance from NYSE Regulation regarding its audit committee composition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
management
-
Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) has announced the formalization of its collaboration with KR8.ai Inc. and the exclusive license to KR8's AI-based software to support the development and commercial launch of its new health and wellness offering - the VITHAR™ AI Health Coach. The company aims to provide personalized health and wellness recommendations by leveraging epigenetic data, genetic insight, and growing patent estate with AI-driven analytic software and proprietary algorithms. The goal is to capture a meaningful share of the Health and Fitness App Market, which is projected to reach $35.7 billion by 2030, through a cost-effective go-to-market strategy. The new app will require users to send a saliva or blood sample, and the technology will combine this information with user health stats, as well as peer-reviewed clinical studies and other verified health resources to provide customized AI-driven health recommendations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.49%
Tags
AI
Rhea-AI Summary
FOXO Technologies Inc. (Ticker: FOXO) received a notice of noncompliance from NYSE Regulation due to the failure to timely file the Company’s Form 10-Q for the period ended September 30, 2023. The Company is committed to regaining compliance with the NYSE American’s continued listing requirements and has taken steps to enhance its financial infrastructure and ensure the highest standards of corporate governance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none

FAQ

What is the current stock price of FOXO Technologies (FOXO)?

The current stock price of FOXO Technologies (FOXO) is $0.2755 as of December 23, 2024.

What is the market cap of FOXO Technologies (FOXO)?

The market cap of FOXO Technologies (FOXO) is approximately 5.1M.

What does FOXO Technologies Inc. specialize in?

FOXO Technologies Inc. specializes in applying epigenetic technology and AI to transform the life insurance industry through advanced risk assessment and consumer engagement.

How does FOXO's technology work?

FOXO uses DNA methylation and AI to identify molecular biomarkers that reveal insights into an individual's health and aging, allowing for more accurate underwriting in life insurance.

What are epigenetic biomarkers?

Epigenetic biomarkers are molecular signs found in DNA that indicate current health status and biological age, which FOXO utilizes to enhance life insurance underwriting.

How is FOXO Technologies Inc. impacting the life insurance industry?

By employing epigenetic technology and AI, FOXO is revolutionizing life insurance underwriting, making it more precise and personalized.

What are some recent achievements of FOXO Technologies Inc.?

Recent milestones include advancements in epigenetic research, development of AI-driven health assessments, and strategic partnerships to enhance their technology platform.

What is FOXO Technologies Inc.’s approach to consumer engagement?

FOXO engages consumers through a platform that provides personalized health insights based on epigenetic biomarkers, enhancing their understanding of personal health and longevity.

Who are FOXO Technologies Inc.'s partners?

FOXO collaborates with leading scientific institutions and industry partners to advance their research and technology applications in the life insurance sector.

What is DNA methylation?

DNA methylation is a biological process where methyl groups are added to DNA, affecting gene expression without altering the DNA sequence. FOXO uses this process to identify health biomarkers.

Where is FOXO Technologies Inc. headquartered?

FOXO Technologies Inc. is headquartered in Minneapolis, as indicated in their latest news release.

What is the future outlook for FOXO Technologies Inc.?

FOXO is focused on continued innovation in epigenetic technology and AI, aiming for sustained growth and expanded applications in the life insurance industry.

FOXO Technologies Inc.

NYSE:FOXO

FOXO Rankings

FOXO Stock Data

5.09M
14.12M
12%
2.26%
0.39%
Health Information Services
Services-commercial Physical & Biological Research
Link
United States of America
MINNEAPOLIS